Skip to content

Increasing the dose of nicotine replacement treatment to individual needs

Increasing the dose of Nicotine Replacement Treatment to individual needs: A pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN24872175
Enrollment
50
Registered
2017-05-18
Start date
2017-04-01
Completion date
Unknown
Last updated
2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking cessation Mental and Behavioural Disorders Smoking cessation

Interventions

Smokers wanting to give up will be given nicotine patches to use for 4 weeks prior to their target quit day and for 4 weeks during their quit attempt. In the four weeks prior to their target quit day,

Sponsors

Fundación Enfisema
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years of age 2. Daily smoker 3. Seeking treatment to quit smoking and willing to use nicotine patches

Exclusion criteria

Exclusion criteria: 1. Pregnant/breastfeeding or planning to conceive in the next 3 months 2. Previous adverse reaction to the nicotine patch 3. Serious medical condition including, cancer and psychiatric illness 4. History of Myocardial infarction 5. Cannot read, write or understand Spanish 6. Current involvement in other interventional research

Design outcomes

Primary

MeasureTime frame
Feasibility of the intervention is assessed by recording the proportion of participants who progress through each stage of increased dosage (42mg, 63mg and 84mg) over the four weeks prior to their Target Quit Day.

Secondary

MeasureTime frame
1. Adherence to treatment will be assessed by examining the frequency of patch use over the 8 weeks and the number of participants who stop using their patches over the 8 weeks 2. Acceptability and helpfulness of the intervention will be measured by asking participants to rate (1-5) how helpful they found their patch over the last week, at each session; and by looking at the frequency of any adverse effects and their intensity 3. Potential efficacy of the intervention will be measured by examining validated abstinence rates at the end of the 8 weeks, changes in carbon monoxide readings, cigarette consumption, enjoyment of smoking and withdrawal symptoms over the first 4 weeks prior to the TQD; and changes in withdrawal symptoms over the 8 weeks

Countries

Argentina

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026